Literature DB >> 7139592

Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.

F Gilbert, G Balaban, P Moorhead, D Bianchi, H Schlesinger.   

Abstract

Specific constitutional chromosome rearrangements have been described in a small number of individuals with two solid childhood tumors, retinoblastoma and Wilms' tumor. On the basis of these observations, a causal relationship between these chromosome abnormalities and tumorigenesis has been postulated. Though a specific constitutional chromosome abnormality has yet to be reported in association with neuroblastoma, another childhood tumor, we now confirm the involvement of a particular chromosome segment in structural abnormalities in cells from this tumor. Deletions or rearrangements of chromosome 1p were found in preparations from four of six neuroblastomas from individuals with normal constitutional karyotypes and in three of four permanent neuroblastoma cell lines. Structural abnormalities resulting in the loss or rearrangement of material from 1p (with the most frequent break point being 1p32 and with all rearrangements involving the apparent loss or rearrangement of material distal to 1p31, always including 1p34 to 1pter), represent the single most common class of chromosome aberrations in neuroblastoma. This suggests that the distal portion of 1p contains at least one gene involved in the development of neuroblastoma.

Entities:  

Mesh:

Year:  1982        PMID: 7139592     DOI: 10.1016/0165-4608(82)90105-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  34 in total

1.  Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.

Authors:  Yoshitaka Miyagawa; Hajime Okita; Hideki Nakaijima; Yasuomi Horiuchi; Ban Sato; Tomoko Taguchi; Masashi Toyoda; Yohko U Katagiri; Junichiro Fujimoto; Jun-Ichi Hata; Akihiro Umezawa; Nobutaka Kiyokawa
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

2.  Capture and characterization of 5-aza-2'-deoxycytidine-treated C3H/10T1/2 cells prior to transformation.

Authors:  S Rainier; A P Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside.

Authors:  S Faraj; M Bahri; S Fougeray; A El Roz; J Fleurence; J Véziers; M D Leclair; E Thébaud; F Paris; S Birklé
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

Review 4.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

5.  Neuroepithelioma (neuroblastoma) arising in an adult. A case report.

Authors:  J Verwey; R Slater; W Kamphorst; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  Isolation of amplified DNA sequences from IMR-32 human neuroblastoma cells: facilitation by fluorescence-activated flow sorting of metaphase chromosomes.

Authors:  N Kanda; R Schreck; F Alt; G Bruns; D Baltimore; S Latt
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  Characterization of N-myc amplification in a human neuroblastoma cell line by clones isolated following the phenol emulsion reassociation technique and by hexagonal field gel electrophoresis.

Authors:  Y Nishi; K Akiyama; B R Korf
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

8.  Loss of heterozygosity in hypotriploid cell cultures from testicular tumours.

Authors:  J M Parrington; L F West; S Povey
Journal:  Hum Genet       Date:  1987-11       Impact factor: 4.132

9.  Tumour karyotype may be important in the prognosis of human neuroblastoma.

Authors:  F Franke; B Rudolph; H Christiansen; J Harbott; F Lampert
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 10.  Karyotypic progression in human tumors.

Authors:  S R Wolman
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.